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Introduction: Allogeneic hematopoietic stem cell transplantation (ASCT) repre-
sents a potentially curative approach for patients with relapsed or refractory acute 
myeloid leukemia (AML). We report the outcome of relapsed/refractory AML 
patients treated with ASCT. 
Method: A retrospective cohort from 1994 to 2013 that included 61 patients 
with diagnosis of relapsed/refractory AML. Outcomes of interest were transplant-
-related mortality (TRM), incidence of acute and chronic graft-versus-host disease 
(GVHD), relapse incidence, progression-free survival (PFS) and overall survival 
(OS). Statistical significance was set at p<0.05.
Results: The median age was 61 years (range 1 to 65). The cumulative incidence 
of 90 days, 1 year, and 3 years TRM were 60%, 26.7%, and 13.3%, respectively 
(p<0.001). The incidence of relapse was 21.7% at 1 year, 13% at 3 years, and 8.7% 
at 5 years. Median OS was estimated to be 8 months (95CI 3.266-12.734) and 
median PFS, 3 months (95CI 1.835-4.165). 
Conclusion: In our cohort, TRM in first years after ASCT remains considerable, 
but ASCT in this setting seems to be a good choice for AML patients with active 
disease. However, novel approaches are needed to reduce TRM and relapse in 
this set of patients.
Keywords: acute myeloid leukemia, heterologous transplantation, bone marrow 
neoplasms.
introduction
Acute myeloid leukemia (AML) is a heterogeneous clonal 
disorder of hematopoietic progenitor cells which lose 
their ability to differentiate normally and to respond to 
normal regulators of proliferation.1,2 Intensified treatment 
and improvement in supportive care have resulted in an 
enhanced outcome for patients with AML. At diagnosis, 
AML patients are evaluated by clinical risk factors and 
are considered for allogeneic stem cell transplantation 
(ASCT) based on the risk factors.3 Cytogenetic abnor-
malities are among the most widely recognized risk factors 
in AML patients.4 AML with karyotype t(8;21), inv(16), 
t(16;16), and t(15;17) are expected to be controlled with 
chemotherapy alone, and patients with these forms of 
AML are thus categorized into a favorable cytogenetic risk 
group.4,5 Therefore, indication of ASCT for patients in 
this group is considered not at the first complete remis-
sion but at the state of relapse, after the second remission 
or just in case of failure to achieve remission.3,5,6 Recent 
results from clinical trials indicate a 1-year overall sur-
vival (OS) rate of 60 to 70%.7-9 In children with AML who 
relapsed post-ASCT and after a second ASCT, it was re-
ported at approximately 30 to 40% by Lee et al.9 In 2013, 
survival outcomes were reported to be similar between 
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adolescents and children with AML following ASCT.10 
Myeloablative preparative regimen used for ASCT in-
duces profound neutropenia and platelet decrease.11 Pro-
longed time of recovery from neutropenia is associated 
with high risk of infections and severe sepsis. Although 
granulocyte colony-stimulate factors can be used to help 
in neutrophil recovery, it delays platelet engraftment as 
well as immune recovery and may increase the incidence 
of graft-versus-host disease (GVHD), transplant-related 
mortality (TRM) and death.2,12 Nevertheless, ASCT rep-
resents a potentially curative approach for patients with 
relapsed or refractory AML in spite of significant TRM 
and comorbidity, such as veno-occlusive disease and sep-
sis.11 Several regimens with different dose intensities have 
been studied as conditioning therapies before ASCT in 
patients with AML.13 In addition, the choice between 
myeloablative conditioning, non-myeloablative regimens 
and reduced intensity conditioning regimens depends on 
the disease behavior as well as patient overall condition 
and tolerated toxicities, even though outcomes can be 
questioned.14 Thus, ASCT for patients with relapsed/re-
fractory disease could represent an important therapeu-
tic option in order to improve survival in an attempt to 
control a novel relapse. 
Herein, we report the results of a retrospective cohort 
with the primary endpoint of assessing outcomes in a 
southern European comprehensive cancer center. We 
analyzed OS, progression-free survival (PFS), and incidence 
of relapse after the second ASCT post-high dose induction 
chemotherapy in patients with relapse/refractory disease. 
The secondary endpoints of this study were the assessment 
of TRM and GVHD rate.
Method 
Design
Our retrospective cohort includes data from January 1994 
to January 2013 collected at the Central Comprehensive 
Cancer Hospital in northern Portugal: the Portuguese 
Oncology Institute (IPO-Porto), Porto, Portugal. The 
study was conducted according to the Declaration of 
Helsinki. Signed written-informed consent form was 
obtained from all patients involved in this study.
Patients
The patient inclusion criteria were the following: con-
firmed diagnosis of relapsed/refractory AML (based on 
morphological findings of the bone marrow aspirates and 
immune-phenotype analysis of leukemic cells by flow 
cytometry or immune histochemical analysis) and ade-
quate hematologic, renal, and hepatic function. Patients 
who did not meet the inclusion criteria were excluded 
from this study. Data were collected from clinical records 
at the participant institution. All patients involved in this 
study were Portuguese Caucasians.
Treatment regimen
ASCT was performed on 61 patients in active disease 
(relapsed/refractory). The preparative regimens and stem 
cell sources differed between the participants.
Endpoints
The primary endpoint of our study was OS, which was 
defined as the period between the date of first recurrence 
diagnosis and death due to the disease/last medical visit. 
Progression-free survival was defined as the period between 
the date of first recurrence diagnosis and the date of sec-
ond recurrence diagnosis. Complete response (CR) was 
considered normocellular bone marrow (≤ 5% blast), pe-
ripheral blood with neutrophils ≥ 1500/µL, absence of 
any AML sign. Partial response (PR) referred to normocel-
lular bone marrow (6 to 25% blasts) or organic sign of 
AML. Failure/no response (NR) included patients with 
clinical disease or bone marrow with ≥ 5% blasts post-
-transplant. The secondary endpoints were TRM and in-
cidence of acute and chronic GVHD.
Statistical analysis
Chi-squared and Wilcoxon-Mann-Whitney tests were used 
to compare the frequency distributions of variables such 
as age, sex, TRM, acute and chronic GVHD rates. We 
analyzed OS and PFS using a Kaplan-Meier curve. All 
statistical tests were two-sided, and p<0.05 was considered 
the threshold of statistical significance. All data analyses 
were performed using IBM® SPSS Statistics, version 22.0 
(Chicago, USA).
results
Patients’ characteristics
Table 1 and Table 2 summarize the characteristics of the 
61 patients involved in our study. Median age was 61 
years (1 to 65) and the majority of patients were older 
than 18 years. Female gender corresponded to 55.7% of 
all patients. With respect to French-American-British 
(FAB) classification, the majority of patients correspond-
ed to M1 (10.3%), M2 (34.5%), M4 (10.3%), and M7 (10.3%). 
The mainstay of our cohort was to evaluate outcome of 
AML patients with active disease. Patients with first re-
lapse were 23 out of 59 (39%); second resistance relapse, 
7 out of 59 (11.9%); disease not treated, 2 out of 59 (3.4%); 
primary resistance relapse, 11 out of 59 (18.6%); graft 
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failure, 11 out of 59 (18.6%); third relapse, 2 out of 59 
(3.4%). Approximately half of patients were treated with 
non-myeloablative regimens (55.7%) and the majority 
had HLA-related disease (83.9%). Also, 54 out of 61 pa-
tients (88.5%) were treated with stem cells from periph-
eral blood source.
TABLE 1 Characteristics of the patients.
Characteristics Patients, n Rate %
Patients analyzed 61 100
Age, years 61 (1-65)
< 2 years 1/61 1.6
2 – 9 years 8/61 13.1
10 – 17 years 5/61 8.2
18 – 45 years 24/61 39.3
> 45 years 23/61 37.7
Sex
Male 27/61 44.3
Female 34/61 55.7
FAB type
M0 2/58 3.4
M1 6/58 10.3
M2 20/58 34.5
M3 1/58 1.7
M4 6/58 10.3
M5 5/58 8.6
M6 1/58 1.7
M7 6/58 10.3
Not classified 11/58 18.9
Missing data 3
FAB: French-American-British classification.
TABLE 2 Characteristics of disease status, preparative 
regimens, and transplant-related issues.
Characteristic Patients, n %
Disease status
First no treated relapse 23/59 39
Second resistance relapse 7/59 11.9
Disease not treated 2/59 3.4
Primary resistant disease 11/59 18.6
Progressive disease 1/59 1.7
Graft failure 11/59 18.6
Third relapse 2/59 3.4
First relapse – responsive disease 1/59 1.7
Second relapse – responsive disease 1/59 1.7
Missing data 2 3.3
(Continue)
TABLE 2 (Cont.) Characteristics of disease status, 
preparative regimens, and transplant-related issues.
Characteristic Patients, n %
Conditioning regimen
Myeloablative 27 44.3
Non-myeloablative 34 55.7
Donor status
Parents 3 4.9
Siblings 48 78.7
Matched unrelated 10 16.4
HLA
Related 47/56 83.9
Mismatched 9/56 16.1
Missing data 5
Stem cell source
Umbilical cord 1/61 1.6
Bone marrow 6/61 9.8
Peripheral blood 54/61 88.5
Best response
Complete response 2/23 8.7
Partial response 3/23 13
Failure or no response 18/23 78.3
Not possible to assess* 38
Censor
Overall mortality 42/61 68.85
Disease-related mortality 27/61 44.26
Transplant-related mortality 15/61 24.59
HLA: anti-human leukocyte antigen; *these data were not possible to assess due to trans-
plant-related mortality or early disease-related mortality prior to response assessment.
Outcomes: Clinical response, overall survival, and progression-
-free survival
In terms of clinical response, 2 out of 23 patients (8.7%) 
presented completed response and 3 out of 23 patients 
(9.8%) presented partial response. The incidence of relapse 
was 13 out of 23 patients (56.5%) in the first 90 days post-
-ASCT; 5 out of 23 (21.7%) in the first year; 3 out of 23 
(13%) in the third year; and 2 out of 23 (8.7%) in the fifth 
year post-ASCT (Table 3). The overall mortality post-ASCT 
in our set of patients with active disease (relapse or refrac-
tory AML) was 42 out of 61 (68.85%): 15 out of 44 patients 
due to TRM and 27 out of 44 patients due to AML (Table 
2). In addition, mortality was higher in the first 90 days 
post-ASCT, 20 out of 42 (47.6%), than in the first year, 18 
out of 44 (42.8%); in the third year, 2 out of 44 (4.7%); and 
in the fifth year, 4 out of 44 (9.5%) post-ASCT, p<0.001. 
Moreover, median PFS was 3 months (95CI 1.835-4.165) 
and median OS was 8 months (95CI 3.266-12.734).
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Transplant-related mortality, disease mortality, and graft-versus-
-host disease
Table 3 summarizes data regarding TRM: 9 out of 15 pa-
tients (60%) in the 90 days post-ASCT, 4 out of 15 (26.7%) 
in the first year, 2 out of 15 patients (13.3%) in the third 
year post-ASCT (p=0.136). Table 3 also shows mortality 
due to AML: 11 out of 27 patients (40.7%) in the first 90 
days post-ASCT; 14 out of 27 (51.83%) in the first year; 
and 4 out of 27 patients (14.8%) in the fifth year post-
ASCT (p=0.005). In spite of the high amount of missing 
data regarding GVHD status throughout our clinical re-
cords, we could verify that 20 out of 47 patients (42.6%) 
presented with acute grade II–IV GVHD and 11 out of 17 
patients (64.7%) presented with chronic grade II–IV GVHD.
discussion 
AML with active disease (relapsed/refractory) remains a 
challenge for clinicians worldwide, especially in patients 
previously treated with ASCT.15 In this setting of patients, 
prognosis is still poor and this group may benefit from 
new drug developments and alternative approaches for 
disease control and delay of a novel relapse.16,17 In patients 
with relapsed AML, depending on cytogenetic profile, age 
and time of first remission, cytarabine-based salvage che-
motherapy is sometimes satisfactory.15,18,19 However, only 
a few randomized studies address this issue, which thus 
remains a gray area.20,21 In second line setting, favorable, 
intermediate or high intermediate group are suitable to 
SWOG 9126 protocol (high dose cytarabine, daunorubicin 
and cyclosporine).22,23 Our cohort did not provide the cy-
togenetic profile of the studied population due to the pres-
ence of active disease and therefore its irrelevance in this 
framework. In addition, we included patients since 1994, 
and, by then, data such as these were not available. ASCT 
should only be proposed to patients with second remission 
in case of HLA-matched donor or HLA-mismatched donor 
depending on age.24 Patients in the high-risk group and 
with time of remission less than 6 months should be re-
ferred to clinical trials or better supportive care.25-27 In our 
cohort, 59 out of 61 patients presented active disease, i.e., 
patients who had failure in previous treatments, including 
previous ASCT. Despite that, our population was rela-
tively heterogeneous; the present manuscript reports the 
experience of a large reference Comprehensive Cancer 
Center in southern Europe that serves a 3 million habitant 
area in the North of Portugal. Most of our patients were 
female and with M1, M2, M4, and M7 FAB classification 
(Table 1). In addition, the donor sample was mostly fam-
ily-related and HLA-related, which favored our results 
(Table 2). In terms of response, we observed 2 out of 23 
(8.7%) complete response patients in our cohort and an 
overall mortality of 68.85% (42 out of 61 patients). This 
data reflects the disease aggressiveness of our set of patients. 
However, it also represents relatively good results compared 
to best supportive care and others approaches previously 
published in the literature.26,28 Interestingly, in 2013, Iva-
noff et al. reported a cohort of 47 patients with acute/
refractory AML, after at least one course of intensive che-
motherapy, treated with 5-azacytidine in three different 
French institutions. The overall response rate was higher 
(38%) than in our cohort (21.7%) and the median OS (9 
months) was also slightly higher than in our study (8 
months).29 However, despite the relatively inferior results 
compared to the French cohort using 5-azacytidine, our 
TABLE 3 Outcomes at 90 days, 1 year, 3 years and 5 years.
Outcomes 90 days 1 year (n, %) 3 years (n, %) 5 years (n, %) Total (n) p-value*
Relapse or progression
Relapse 13/23 (56.5%) 5/23 (21.7%) 3/23 (13%) 2/23 (8.7%) 23 NR
Missing data - - - - 38
Overall survival
Mortality 20/42 (47.6) 18/42 (42.8%) 2/42 (4.7%) 4/42 (9.5%) 42 <0.001
Missing data 0
TRM
Mortality – TRM 9/15 (60%) 4/15 (26.7%) 2/15 (13.3%) 0 15 0.136
Missing data - - - - 0
Disease mortality
Mortality – AML 11/27 (40.7%) 14/27 (51.8%) 0 4/27 (14.8%) 27 0.005
Missing data - - - - 0
n: number of patients; *Chi-square test; NR: not reported; TRM: transplant-related mortality; AML: acute myeloid leukemia.
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cohort provided a high number of patients (61 versus 47) 
and a similar OS to the 5-azacytidine study. Of note, ran-
domized clinical trials are warranted in order to compare 
the real effectiveness of both approaches in relapsed/re-
fractory AML patients. In our cohort, conditioning regimen 
data are reported in Table 2 and Table 3. Myeloablative 
and non-myeloablative regimen were well balanced and 
applied at the physician’s discretion and according to 
institutional protocol indications.26 In 2012, Bornhäuser 
et al.30 published an interesting phase III trial with 99 
patients randomly assigned to receive reduced-intensity 
regimen and 96 patients to receive standard conditioning 
regimen. The incidence of non-relapse mortality, relapse 
incidence at 3 years, PFS at 3 years, and OS at 3 years did 
not differ significantly between groups.30 However, grade 
III-IV toxicities were less common in the reduced inten-
sity group. This trial was stopped early due to a slow inclu-
sion of patients. The authors concluded that reduced 
intensity conditioning had similar survival outcomes 
compared to standard regimens with few side effects and 
thus should be offered to AML patients aged less than 60 
years in first complete remission.30 Therefore, we believe 
that the conditioning regimen used in our study did not 
affect the outcomes of our set of patients as a confound-
ing factor. However, for those patients who relapse after 
ASCT, prognosis is particularly poor with limited report-
ed literature addressing this issue. In our study, the major-
ity of patients relapsed in the first 90 days post-ASCT 
(56.5%) and a minority relapsed 5 years after ASCT (8.7%) 
(Table 3). Likewise, mortality in the first 90 days (47.6%) 
and after 1 year (42.8%) were higher than the mortality at 
3 (4.7%) and 5 years (9.5%) (p<0.001). This fact could be 
due to the extreme agressiveness of the disease, high 
toxicity grades, and difficult clinical management. In 
addition, TRM tended to occur in the first 90 days post-
-ASCT (60%) compared to the first (26.7%) and third years 
(13.3%) post-ASCT (p=0.136). In 2013, Lee et al.9 published 
a retrospective study in which they reviewed 49 patients 
with AML who received ASCT and who had subsequently 
relapsed. The 5-year OS was 31.6% and all three recipients 
of second ASCT died. Thus, Lee et al. concluded that treat-
ment with curative intent was able to save a minor but 
important subset of patients with AML who relapsed after 
ASCT.9 Notably, even though our patients have been treat-
ed with prophylaxis to GVHD with cyclosporine and my-
cophenolate mofetil, grade II-IV acute GVHD occurred in 
a considerable number of patients. In 2012, another South 
Korean study reported a set of 142 consecutive AML pa-
tients treated with ASCT who also presented high acute 
(37.6-53.7%) and chronic (8.9-19.5%) GVHD incidence.31 
In addition, another study32 by Baron et al. reported that 
grade III-IV and extensive GVHD had influence in OS of 
AML patients treated with ASCT. Thus, improvement in 
prevention and treatment of severe GVHD could have 
influence in prognosis of those patients, even though it is 
a difficult issue to overcome.32
conclusion
In conclusion, relapsed/refractory AML post-ASCT re-
mains a very aggressive disease.26 Many efforts throughout 
the clinical and scientific communities are underway in 
order to develop novel strategies for best treatment 
care.21,25,27 Nevertheless, there is still a gray area where the 
highlights in patient’s clinical managements with respect 
to a best therapeutic choice and side-effects control are 
the mainstay of this field. In our cohort, TRM remains 
considerable, but ASCT in this setting seems to be a good 
choice for AML patients with active disease. However, new 
approaches are needed in order to reduce TRM, GVHD 
incidence and relapse in this set of patients.
resuMo
Resultados do transplante alogênico de células-tronco em 
doentes com leucemia mieloide aguda com doença ativa: 
experiência de um único Centro Oncológico Europeu
Introdução: o transplante alogênico de células-tronco 
hematopoiéticas (TCTH-alo) representa uma abordagem 
potencialmente curativa para pacientes com leucemia 
mieloide aguda (LMA) recorrente ou refratária. Nosso 
trabalho apresenta o resultado de pacientes com recaída 
ou doença refratária tratados com TCTH-alo.
Método: coorte retrospectiva incluindo 61 pacientes de 
1994 a 2013 com diagnóstico de recidiva/LMA refratária. 
Os desfechos de interesse foram mortalidade relacionada 
ao transplante (MRT), incidência da doença aguda e crô-
nica do enxerto contra hospedeiro (DECH), incidência 
de recaídas, sobrevida livre de progressão (PFS – progression-
-free survival) e sobrevida global (SG). A significância esta-
tística foi considerada para p<0,05. 
Resultados: a média de idade foi de 61 anos (variação de 
1 a 65). A incidência cumulativa de 90 dias, 1 ano e 3 anos 
de MRT foram de 60%, 26,7% e 13,3%, respectivamente 
(p<0,001). A incidência de recaída foi de 21,7% em 1 ano, 
13% em 3 anos e 8,7% em 5 anos. A SG mediana foi esti-
mada em 8 meses (IC 95% 3,266-12,734) e a mediana de 
PFS, em 3 meses (IC 95% 1,835-4,165). 
Conclusão: em nossa coorte, MRT no primeiro ano após 
o transplante permanece considerável, mas TCTH-alo 
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nesse cenário parece ser uma boa opção para pacientes com 
LMA ativa. No entanto, novas abordagens são necessárias 
para reduzir MRT e recaída nesse conjunto de pacientes.
Palavras-chave: leucemia mieloide aguda, transplante 
heterólogo, neoplasias da medula óssea.
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